Astrazeneca patents expiration
1. Airsupra patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9415009 | ASTRAZENECA | Compositions, methods and systems for respiratory delivery of two or more active agents |
May, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 10, 2026 |
Drugs and Companies using ALBUTEROL SULFATE; BUDESONIDE ingredient
Market Authorisation Date: 10 January, 2023
Treatment: As-needed treatment or prevention of bronchoconstriction and reduction of the risk of exacerbations in patients with asthma 18 years of age and older
Dosage: AEROSOL, METERED;INHALATION
AIRSUPRA family patents
2. Bevespi Aerosphere patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9463161 | ASTRAZENECA | Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems |
May, 2030
(6 years from now) | |
| US8808713 | ASTRAZENECA | Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems |
May, 2030
(6 years from now) | |
| US9415009 | ASTRAZENECA | Compositions, methods and systems for respiratory delivery of two or more active agents |
May, 2030
(6 years from now) | |
| US10716753 | ASTRAZENECA | Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems |
May, 2030
(6 years from now) | |
| US8324266 | ASTRAZENECA | Compositions, methods and systems for respiratory delivery of two or more active agents |
May, 2030
(6 years from now) | |
| US8703806 | ASTRAZENECA | Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents |
May, 2030
(6 years from now) | |
| US8815258 | ASTRAZENECA | Compositions, methods and systems for respiratory delivery of two or more active agents |
Mar, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 25, 2019 |
Drugs and Companies using FORMOTEROL FUMARATE; GLYCOPYRROLATE ingredient
Market Authorisation Date: 25 April, 2016
Treatment: Use for the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)
Dosage: AEROSOL, METERED;INHALATION
BEVESPI AEROSPHERE family patents
3. Brilinta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6251910 | ASTRAZENECA | 1,2,3-triazolo[4,5-d]pyrimidines as P2T receptor antagonists |
Jul, 2018
(5 years ago) | |
| US7250419 | ASTRAZENECA | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition |
Dec, 2019
(4 years ago) | |
| US6525060 | ASTRAZENECA | Triazolo(4,5-d)pyrimidine compounds |
Dec, 2019
(4 years ago) | |
| US7265124 | ASTRAZENECA | Cristalline and amorphous form of a triazolo (4,5-D) pyridimine compound |
Jul, 2021
(2 years ago) | |
| USRE46276 | ASTRAZENECA | Triazolo(4,5-D)pyrimidine compounds |
Oct, 2024
(6 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
USRE46276 (Pediatric) | ASTRAZENECA | Triazolo(4,5-D)pyrimidine compounds |
Apr, 2025
(1 year, 5 days from now) | |
| US8425934 | ASTRAZENECA | Pharmaceutical compositions |
Apr, 2030
(5 years from now) | |
|
US8425934 (Pediatric) | ASTRAZENECA | Pharmaceutical compositions |
Oct, 2030
(6 years from now) | |
| US10300065 | ASTRAZENECA | Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction |
Jan, 2036
(11 years from now) | |
|
US10300065 (Pediatric) | ASTRAZENECA | Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction |
Jul, 2036
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-848) | Nov 05, 2023 |
| M(M-283) | May 09, 2025 |
| Pediatric Exclusivity(PED) | Nov 09, 2025 |
| New Indication(I-851) | May 28, 2023 |
| New Strength(NS) | Sep 03, 2018 |
| New Indication(I-714) | Sep 03, 2018 |
| New Chemical Entity Exclusivity(NCE) | Jul 20, 2016 |
Drugs and Companies using TICAGRELOR ingredient
NCE-1 date: 09 November, 2024
Market Authorisation Date: 03 September, 2015
Treatment: Reducing the rate of cardiovascular death, myocardial infarction, and stroke in a patient receiving 75-100 mg aspirin daily and having or who had acute coronary syndrome by administering 60 mg ticagre...
Dosage: TABLET;ORAL
BRILINTA family patents
4. Calquence patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7459554 | ASTRAZENECA | Imidazopyrazine tyrosine kinase inhibitors |
Nov, 2026
(2 years from now) | |
| US9290504 | ASTRAZENECA | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors |
Jul, 2032
(8 years from now) | |
| US9796721 | ASTRAZENECA | Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide |
Jul, 2036
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10239883 | ASTRAZENECA | 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors |
Jul, 2032
(8 years from now) | |
| US9758524 | ASTRAZENECA | 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors |
Jul, 2032
(8 years from now) | |
| US10272083 | ASTRAZENECA | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
Jan, 2035
(10 years from now) | |
| US11771696 | ASTRAZENECA | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
Jan, 2035
(10 years from now) | |
| US10167291 | ASTRAZENECA | Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl) pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide |
Jul, 2036
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-175) | Oct 31, 2024 |
| Orphan Drug Exclusivity(ODE-274) | Nov 21, 2026 |
| New Indication(I-817) | Nov 21, 2022 |
| New Chemical Entity Exclusivity(NCE) | Oct 31, 2022 |
Drugs and Companies using ACALABRUTINIB ingredient
NCE-1 date: 31 October, 2021
Market Authorisation Date: 31 October, 2017
Treatment: Treatment of adult patients with chronic lymphocytic leukemia; Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; Treatment of adult patients with prev...
Dosage: CAPSULE;ORAL
CALQUENCE family patents
5. Calquence patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7459554 | ASTRAZENECA | Imidazopyrazine tyrosine kinase inhibitors |
Nov, 2026
(2 years from now) | |
| US9290504 | ASTRAZENECA | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors |
Jul, 2032
(8 years from now) | |
| US11059829 | ASTRAZENECA | Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide maleate |
Jul, 2036
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10239883 | ASTRAZENECA | 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors |
Jul, 2032
(8 years from now) | |
| US9758524 | ASTRAZENECA | 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors |
Jul, 2032
(8 years from now) | |
| US11771696 | ASTRAZENECA | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
Jan, 2035
(10 years from now) | |
| US10272083 | ASTRAZENECA | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
Jan, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 31, 2022 |
Drugs and Companies using ACALABRUTINIB MALEATE ingredient
NCE-1 date: 31 October, 2021
Market Authorisation Date: 03 August, 2022
Treatment: Treatment of adult patients with previously untreated chronic lymphocytic leukemia in combination with obinutuzumab; Treatment of adult patients with mantle cell lymphoma who have received at least on...
Dosage: TABLET;ORAL
CALQUENCE family patents
6. Daliresp patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5712298 | ASTRAZENECA | Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors |
Jan, 2020
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8431154 | ASTRAZENECA | Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient |
Feb, 2023
(1 year, 2 months ago) | |
| US9468598 | ASTRAZENECA | Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient |
Feb, 2023
(1 year, 2 months ago) | |
| US8604064 | ASTRAZENECA | Process for the preparation of roflumilast |
Mar, 2024
(a month ago) | |
| US8536206 | ASTRAZENECA | Process for the preparation of roflumilast |
Mar, 2024
(a month ago) | |
| US8618142 | ASTRAZENECA | Process for the preparation of roflumilast |
Mar, 2024
(a month ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-208) | Aug 31, 2020 |
| New Strength(NS) | Jan 23, 2021 |
| New Dosing Schedule(D-171) | Jan 23, 2021 |
| New Chemical Entity Exclusivity(NCE) | Feb 28, 2016 |
Drugs and Companies using ROFLUMILAST ingredient
NCE-1 date: 28 February, 2015
Market Authorisation Date: 23 January, 2018
Treatment: Treatment to reduce the risk of copd exacerbations in patients with severe copd associated with chronic bronchitis and a history of exacerbations
Dosage: TABLET;ORAL
DALIRESP family patents
7. Epanova patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9050309 | ASTRAZENECA | DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form |
Jan, 2033
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5792795 | ASTRAZENECA | Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids |
May, 2020
(3 years ago) | |
| US5948818 | ASTRAZENECA | Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids |
May, 2020
(3 years ago) | |
| US9132112 | ASTRAZENECA | Type A gelatin capsule containing PUFA in free acid form |
Feb, 2025
(9 months from now) | |
| US8383678 | ASTRAZENECA | Type a gelatin capsule containing PUFA in free acid form |
Feb, 2025
(9 months from now) | |
| US9012501 | ASTRAZENECA | Type A gelatin capsule containing PUFA in free acid form |
Feb, 2025
(9 months from now) | |
| US7960370 | ASTRAZENECA | Type A gelatin capsule containing PUFA in free acid form |
Dec, 2026
(2 years from now) | |
| US10117844 | ASTRAZENECA | DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form |
Jan, 2033
(8 years from now) | |
| US9050308 | ASTRAZENECA | DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form |
Jan, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 05, 2019 |
Drugs and Companies using OMEGA-3-CARBOXYLIC ACIDS ingredient
NCE-1 date: 05 May, 2018
Market Authorisation Date: 05 May, 2014
Treatment: Treatment of hypertriglyceridemia; Treatment of severe hypertriglyceridemia (500 mg/dl) in adult patients as an adjunct to diet
Dosage: CAPSULE;ORAL
EPANOVA family patents
8. Faslodex patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8466139 | ASTRAZENECA | Formulation |
Jan, 2021
(3 years ago) | |
| US8329680 | ASTRAZENECA | Formulation |
Jan, 2021
(3 years ago) | |
| US6774122 | ASTRAZENECA | Formulation |
Jan, 2021
(3 years ago) | |
| US7456160 | ASTRAZENECA | Formulation |
Jan, 2021
(3 years ago) | |
|
US6774122 (Pediatric) | ASTRAZENECA | Formulation |
Jul, 2021
(2 years ago) | |
|
US7456160 (Pediatric) | ASTRAZENECA | Formulation |
Jul, 2021
(2 years ago) | |
|
US8329680 (Pediatric) | ASTRAZENECA | Formulation |
Jul, 2021
(2 years ago) | |
|
US8466139 (Pediatric) | ASTRAZENECA | Formulation |
Jul, 2021
(2 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-725) | Feb 19, 2019 |
| New Indication(I-749) | Aug 25, 2020 |
| New Dosing Schedule(D-126) | Sep 09, 2013 |
| M(M-103) | May 17, 2014 |
| Pediatric Exclusivity(PED) | Mar 09, 2014 |
| M(M-123) | Nov 09, 2015 |
Drugs and Companies using FULVESTRANT ingredient
Market Authorisation Date: 25 April, 2002
Treatment: Treatment of hr-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with palbociclib in women with disease progression after endocrin...
Dosage: SOLUTION;INTRAMUSCULAR
FASLODEX family patents
9. Iressa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5770599 | ASTRAZENECA | Quinazoline derivatives |
May, 2017
(6 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5457105 | ASTRAZENECA | Quinazoline derivatives useful for treatment of neoplastic disease |
Jan, 2013
(11 years ago) | |
| US5616582 | ASTRAZENECA | Quinazoline derivatives as anti-proliferative agents |
Jan, 2013
(11 years ago) | |
Drugs and Companies using GEFITINIB ingredient
Market Authorisation Date: 05 May, 2003
Treatment: Treatment of non-small cell lung cancer
Dosage: TABLET;ORAL
IRESSA family patents
10. Koselugo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8178693 | ASTRAZENECA | N3 alkylated benzimidazole derivatives as MEK inhibitors |
Mar, 2023
(1 year, 1 month ago) | |
| US7425637 | ASTRAZENECA | N3 alkylated benzimidazole derivatives as MEK inhibitors |
Mar, 2024
(a month ago) | |
| US9562017 | ASTRAZENECA | Hydrogen sulfate salt |
Dec, 2026
(2 years from now) | |
| US9156795 | ASTRAZENECA | Hydrogen sulfate salt |
Dec, 2026
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11813246 | ASTRAZENECA | Pharmaceutical composition |
Mar, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 10, 2025 |
| Orphan Drug Exclusivity(ODE-288) | Apr 10, 2027 |
Drugs and Companies using SELUMETINIB SULFATE ingredient
NCE-1 date: 10 April, 2024
Market Authorisation Date: 10 April, 2020
Treatment: Treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (nf1) who have symptomatic, inoperable plexiform neurofibromas (pn)
Dosage: CAPSULE;ORAL
KOSELUGO family patents
11. Lokelma patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10413569 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Feb, 2032
(7 years from now) | |
| US11406662 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Feb, 2032
(7 years from now) | |
| US8802152 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Apr, 2032
(7 years from now) | |
| US8877255 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Oct, 2033
(9 years from now) | |
| US9913860 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Oct, 2033
(9 years from now) | |
| US10695365 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Oct, 2033
(9 years from now) | |
| US10300087 | ASTRAZENECA | Extended use zirconium silicate compositions and methods of use thereof |
Oct, 2035
(11 years from now) | |
| US9592253 | ASTRAZENECA | Extended use zirconium silicate compositions and methods of use thereof |
Oct, 2035
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6332985 | ASTRAZENECA | Process for removing toxins from bodily fluids using zirconium or titanium microporous compositions |
Mar, 2019
(5 years ago) | |
| US8808750 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Feb, 2032
(7 years from now) | |
| US9844567 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Feb, 2032
(7 years from now) | |
| US9861658 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Feb, 2032
(7 years from now) | |
| US10335432 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Feb, 2032
(7 years from now) | |
| US10398730 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Feb, 2032
(7 years from now) | |
| US11738044 | ASTRAZENECA | Extended use zirconium silicate compositions and methods of use thereof |
Oct, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 18, 2023 |
| M(M-261) | Apr 24, 2023 |
Drugs and Companies using SODIUM ZIRCONIUM CYCLOSILICATE ingredient
NCE-1 date: 18 May, 2022
Market Authorisation Date: 18 May, 2018
Treatment: Treatment of hyperkalemia in adults
Dosage: FOR SUSPENSION;ORAL
LOKELMA family patents
12. Lynparza patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7151102 | ASTRAZENECA | Phthalazinone derivatives |
Apr, 2022
(1 year, 11 months ago) | |
| US7981889 | ASTRAZENECA | Phthalazinone derivatives |
Oct, 2024
(5 months from now) | |
| US7449464 | ASTRAZENECA | Phthalazinone derivatives |
Oct, 2024
(5 months from now) | |
| US8247416 | ASTRAZENECA | Phthalazinone derivative |
Sep, 2028
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8912187 | ASTRAZENECA | Phthalazinone derivatives |
Mar, 2024
(a month ago) | |
| US9169235 | ASTRAZENECA | Phthalazinone derivatives |
Mar, 2024
(a month ago) | |
| US9566276 | ASTRAZENECA | Phthalazinone derivatives |
Mar, 2024
(a month ago) | |
| US8071579 | ASTRAZENECA | DNA damage repair inhibitors for the treatment of cancer |
Aug, 2027
(3 years from now) | |
| US8143241 | ASTRAZENECA | DNA damage repair inhibitors for treatment of cancer |
Aug, 2027
(3 years from now) | |
| US11633396 | ASTRAZENECA | Immediate release pharmaceutical formulation of 4-[3-(4- cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H- phthalazin-1-one |
Oct, 2029
(5 years from now) | |
| US8475842 | ASTRAZENECA | Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one |
Dec, 2029
(5 years from now) | |
| US8859562 | ASTRAZENECA | Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer |
Aug, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-83) | Dec 19, 2021 |
| Orphan Drug Exclusivity(ODE) | Dec 19, 2021 |
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
Drugs and Companies using OLAPARIB ingredient
NCE-1 date: 19 December, 2018
Market Authorisation Date: 19 December, 2014
Treatment: Treatment of hr-negative, her-2 negative, gbrca-mutated metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting; Treatment of deleterious ...
Dosage: CAPSULE;ORAL; TABLET;ORAL
LYNPARZA family patents
13. Nexium patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6875872 | ASTRAZENECA | Compounds |
May, 2014
(9 years ago) | |
| US5900424 | ASTRAZENECA | Omeprazole magnesium salt form |
May, 2016
(7 years ago) | |
| US6369085 | ASTRAZENECA | Form of S-omeprazole |
May, 2018
(5 years ago) | |
| US7411070 | ASTRAZENECA | Form of S-omeprazole |
May, 2018
(5 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5877192 | ASTRAZENECA | Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole |
May, 2014
(9 years ago) | |
| US5690960 | ASTRAZENECA | Pharmaceutical formulation of omeprazole |
Nov, 2014
(9 years ago) | |
|
US6875872 (Pediatric) | ASTRAZENECA | Compounds |
Nov, 2014
(9 years ago) | |
|
US5877192 (Pediatric) | ASTRAZENECA | Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole |
Nov, 2014
(9 years ago) | |
| US5714504 | ASTRAZENECA | Compositions |
Feb, 2015
(9 years ago) | |
|
US5690960 (Pediatric) | ASTRAZENECA | Pharmaceutical formulation of omeprazole |
May, 2015
(8 years ago) | |
|
US5714504 (Pediatric) | ASTRAZENECA | Compositions |
Aug, 2015
(8 years ago) | |
|
US5900424 (Pediatric) | ASTRAZENECA | Omeprazole magnesium salt form |
Nov, 2016
(7 years ago) | |
| US8466175 | ASTRAZENECA | Form of S-omeprazole |
May, 2018
(5 years ago) | |
| US6191148 | ASTRAZENECA | Omerazole process and compositions thereof |
Oct, 2018
(5 years ago) | |
| US6147103 | ASTRAZENECA | Omeprazole process and compositions thereof |
Oct, 2018
(5 years ago) | |
| US6166213 | ASTRAZENECA | Omeprazole process and compositions thereof |
Oct, 2018
(5 years ago) | |
|
US7411070 (Pediatric) | ASTRAZENECA | Form of S-omeprazole |
Nov, 2018
(5 years ago) | |
|
US6369085 (Pediatric) | ASTRAZENECA | Form of S-omeprazole |
Nov, 2018
(5 years ago) | |
|
US8466175 (Pediatric) | ASTRAZENECA | Form of S-omeprazole |
Nov, 2018
(5 years ago) | |
|
US6191148 (Pediatric) | ASTRAZENECA | Omerazole process and compositions thereof |
Apr, 2019
(5 years ago) | |
|
US6166213 (Pediatric) | ASTRAZENECA | Omeprazole process and compositions thereof |
Apr, 2019
(5 years ago) | |
|
US6147103 (Pediatric) | ASTRAZENECA | Omeprazole process and compositions thereof |
Apr, 2019
(5 years ago) | |
| US6428810 | ASTRAZENECA | Pharmaceutical formulation comprising omeprazole |
Nov, 2019
(4 years ago) | |
|
US6428810 (Pediatric) | ASTRAZENECA | Pharmaceutical formulation comprising omeprazole |
May, 2020
(3 years ago) | |
Drugs and Companies using ESOMEPRAZOLE MAGNESIUM ingredient
Market Authorisation Date: 20 February, 2001
Treatment: General use claim submitted for 12 nexium patients stating 'pertinent to the capsule formulation for nexium and its indications for the treatment of gerd and eradication of h.pylori to reduce the risk...
Dosage: CAPSULE, DELAYED REL PELLETS;ORAL; FOR SUSPENSION, DELAYED RELEASE;ORAL
NEXIUM family patents
14. Nexium Iv patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5877192 | ASTRAZENECA | Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole |
May, 2014
(9 years ago) | |
|
US5877192 (Pediatric) | ASTRAZENECA | Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole |
Nov, 2014
(9 years ago) | |
| US6143771 | ASTRAZENECA | Compounds |
May, 2015
(8 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-138) | Mar 04, 2017 |
| New Indication(I-679) | Mar 04, 2017 |
Drugs and Companies using ESOMEPRAZOLE SODIUM ingredient
Market Authorisation Date: 31 March, 2005
Treatment: Risk reduction of rebleeding in pts following therapeutic endoscopy for acute bleeding gastric or duodenal ulcers in adults.
Dosage: INJECTABLE;INTRAVENOUS
NEXIUM IV family patents
15. Prilosec patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6191148 | ASTRAZENECA | Omerazole process and compositions thereof |
Oct, 2018
(5 years ago) | |
| US6166213 | ASTRAZENECA | Omeprazole process and compositions thereof |
Oct, 2018
(5 years ago) | |
| US6147103 | ASTRAZENECA | Omeprazole process and compositions thereof |
Oct, 2018
(5 years ago) | |
| US6150380 | ASTRAZENECA | Crystalline form of omeprazole |
Nov, 2018
(5 years ago) | |
|
US6147103 (Pediatric) | ASTRAZENECA | Omeprazole process and compositions thereof |
Apr, 2019
(5 years ago) | |
|
US6166213 (Pediatric) | ASTRAZENECA | Omeprazole process and compositions thereof |
Apr, 2019
(5 years ago) | |
|
US6191148 (Pediatric) | ASTRAZENECA | Omerazole process and compositions thereof |
Apr, 2019
(5 years ago) | |
|
US6150380 (Pediatric) | ASTRAZENECA | Crystalline form of omeprazole |
May, 2019
(4 years ago) | |
Drugs and Companies using OMEPRAZOLE ingredient
Market Authorisation Date: 05 October, 1995
Treatment: NA
Dosage: CAPSULE, DELAYED REL PELLETS;ORAL
PRILOSEC family patents
16. Prilosec Otc patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5690960 | ASTRAZENECA | Pharmaceutical formulation of omeprazole |
Nov, 2014
(9 years ago) | |
| US5753265 | ASTRAZENECA | Multiple unit pharmaceutical preparation |
Jun, 2015
(8 years ago) | |
| US5817338 | ASTRAZENECA | Multiple unit tableted dosage form of omeprazole |
Oct, 2015
(8 years ago) | |
| US5900424 | ASTRAZENECA | Omeprazole magnesium salt form |
May, 2016
(7 years ago) | |
| US6428810 | ASTRAZENECA | Pharmaceutical formulation comprising omeprazole |
Nov, 2019
(4 years ago) | |
| US6403616 | ASTRAZENECA | Chemical process and pharmaceutical formulation |
Nov, 2019
(4 years ago) | |
Drugs and Companies using OMEPRAZOLE MAGNESIUM ingredient
Market Authorisation Date: 20 June, 2003
Treatment: NA
Dosage: TABLET, DELAYED RELEASE;ORAL
PRILOSEC OTC family patents
17. Pulmicort Flexhaler patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6287540 | ASTRAZENECA | Formulation for inhalation |
Jan, 2018
(6 years ago) | |
| US6027714 | ASTRAZENECA | Formulation for inhalation |
Jan, 2018
(6 years ago) | |
| US7143764 | ASTRAZENECA | Inhalation device |
Mar, 2018
(6 years ago) | |
| US6142145 | ASTRAZENECA | Inhalation device |
May, 2018
(5 years ago) | |
Drugs and Companies using BUDESONIDE ingredient
Market Authorisation Date: 12 July, 2006
Treatment: Maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients six years of age or older, including patients requiring oral corticosteroid therapy for asthma
Dosage: POWDER, METERED;INHALATION
PULMICORT FLEXHALER family patents
18. Pulmicort Respules patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7524834 | ASTRAZENECA | Sterile powders, formulations, and methods for producing the same |
Nov, 2018
(5 years ago) | |
| US6899099 | ASTRAZENECA | Method for treating a respiratory disease |
Dec, 2018
(5 years ago) | |
| US6598603 | ASTRAZENECA | Method for treating respiratory diseases |
Dec, 2018
(5 years ago) | |
|
US7524834 (Pediatric) | ASTRAZENECA | Sterile powders, formulations, and methods for producing the same |
May, 2019
(4 years ago) | |
|
US6598603 (Pediatric) | ASTRAZENECA | Method for treating respiratory diseases |
Jun, 2019
(4 years ago) | |
|
US6899099 (Pediatric) | ASTRAZENECA | Method for treating a respiratory disease |
Jun, 2019
(4 years ago) | |
Drugs and Companies using BUDESONIDE ingredient
Market Authorisation Date: 08 August, 2000
Treatment: Treatment of asthma (maintenance and prophylactic therapy); Once daily treatment of asthma with nebulized budesonide
Dosage: SUSPENSION;INHALATION
PULMICORT RESPULES family patents
19. Seroquel Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5948437 | ASTRAZENECA | Pharmaceutical compositions using thiazepine |
May, 2017
(6 years ago) | |
|
US5948437 (Pediatric) | ASTRAZENECA | Pharmaceutical compositions using thiazepine |
Nov, 2017
(6 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-575) | Oct 08, 2011 |
| New Indication(I-574) | Oct 08, 2011 |
| New Dosing Schedule(D-117) | Oct 08, 2011 |
| Pediatric Exclusivity(PED) | Apr 08, 2012 |
| New Indication(I-576) | Oct 08, 2011 |
| New Indication(I-618) | Dec 02, 2012 |
Drugs and Companies using QUETIAPINE FUMARATE ingredient
Market Authorisation Date: 17 May, 2007
Treatment: Treatment of schizophrenia
Dosage: TABLET, EXTENDED RELEASE;ORAL
SEROQUEL XR family patents
20. Symbicort patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6641800 | ASTRAZENECA | Pressurized aerosol compositions comprising powdered medicament dispersed in hydrofluoroalkane |
Sep, 2012
(11 years ago) | |
| US5972919 | ASTRAZENECA | Combination of a bronchodilator and a steroidal anti-inflammatory drug for the treatment of respiratory disorders, as well as its use and the preparation thereof |
Dec, 2012
(11 years ago) | |
| US5674860 | ASTRAZENECA | Combination of a bronchodilator and a steroidal anti-inflammatory drug for the treatment of respiratory disorders |
Oct, 2014
(9 years ago) | |
| US6123924 | ASTRAZENECA | Pressurized aerosol inhalation compositions |
Sep, 2017
(6 years ago) | |
|
US6123924 (Pediatric) | ASTRAZENECA | Pressurized aerosol inhalation compositions |
Mar, 2018
(6 years ago) | |
| US8461211 | ASTRAZENECA | Use for budesonide and formoterol |
Sep, 2018
(5 years ago) | |
| US7897646 | ASTRAZENECA | Use for budesonide and formoterol |
Sep, 2018
(5 years ago) | |
| US7367333 | ASTRAZENECA | Inhalation device |
Nov, 2018
(5 years ago) | |
|
US8461211 (Pediatric) | ASTRAZENECA | Use for budesonide and formoterol |
Mar, 2019
(5 years ago) | |
|
US7897646 (Pediatric) | ASTRAZENECA | Use for budesonide and formoterol |
Mar, 2019
(5 years ago) | |
|
US7367333 (Pediatric) | ASTRAZENECA | Inhalation device |
May, 2019
(4 years ago) | |
| US7967011 | ASTRAZENECA | Inhalation device |
Aug, 2021
(2 years ago) | |
|
US7967011 (Pediatric) | ASTRAZENECA | Inhalation device |
Feb, 2022
(2 years ago) | |
| US7759328 | ASTRAZENECA | Composition for inhalation |
Jan, 2023
(1 year, 2 months ago) | |
| US8575137 | ASTRAZENECA | Composition for inhalation |
Jan, 2023
(1 year, 2 months ago) | |
| US8143239 | ASTRAZENECA | Composition for inhalation |
Jan, 2023
(1 year, 2 months ago) | |
| US10166247 | ASTRAZENECA | Composition for inhalation |
Jan, 2023
(1 year, 2 months ago) | |
| US11311558 | ASTRAZENECA | Composition for inhalation |
Jan, 2023
(1 year, 2 months ago) | |
|
US10166247 (Pediatric) | ASTRAZENECA | Composition for inhalation |
Jul, 2023
(8 months ago) | |
|
US11311558 (Pediatric) | ASTRAZENECA | Composition for inhalation |
Jul, 2023
(8 months ago) | |
|
US7759328 (Pediatric) | ASTRAZENECA | Composition for inhalation |
Jul, 2023
(8 months ago) | |
|
US8143239 (Pediatric) | ASTRAZENECA | Composition for inhalation |
Jul, 2023
(8 months ago) | |
|
US8575137 (Pediatric) | ASTRAZENECA | Composition for inhalation |
Jul, 2023
(8 months ago) | |
| US8875699 | ASTRAZENECA | Inhaler cap strap |
Nov, 2024
(6 months from now) | |
|
US8875699 (Pediatric) | ASTRAZENECA | Inhaler cap strap |
May, 2025
(1 year, 15 days from now) | |
| US7587988 | ASTRAZENECA | Inhaler device counter |
Apr, 2026
(1 year, 11 months from now) | |
|
US7587988 (Pediatric) | ASTRAZENECA | Inhaler device counter |
Oct, 2026
(2 years from now) | |
| US8387615 | ASTRAZENECA | Inhaler cap strap |
Mar, 2027
(2 years from now) | |
|
US8387615 (Pediatric) | ASTRAZENECA | Inhaler cap strap |
Sep, 2027
(3 years from now) | |
| US8528545 | ASTRAZENECA | Inhaler device that reduces the risk for miscounting a dosage |
Oct, 2028
(4 years from now) | |
| US8616196 | ASTRAZENECA | Inhalation device and a method for assembling said inhalation device |
Apr, 2029
(4 years from now) | |
|
US8528545 (Pediatric) | ASTRAZENECA | Inhaler device that reduces the risk for miscounting a dosage |
Apr, 2029
(4 years from now) | |
|
US8616196 (Pediatric) | ASTRAZENECA | Inhalation device and a method for assembling said inhalation device |
Oct, 2029
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-582) | Feb 27, 2012 |
| M(M-210) | Sep 11, 2020 |
| New Patient Population(NPP) | Jan 27, 2020 |
| M(M-214) | Dec 20, 2020 |
| Pediatric Exclusivity(PED) | Jul 27, 2020 |
Drugs and Companies using BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE ingredient
Market Authorisation Date: 21 July, 2006
Treatment: Use for the treatment of asthma; Use for the treatment of chronic obstructive pulmonary disease (copd), including chronic bronchitis and emphysema; Use for maintenance treatment of chronic obstructive...
Dosage: AEROSOL, METERED;INHALATION
SYMBICORT family patents
21. Symbicort Aerosphere patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10716753 | ASTRAZENECA | Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems |
May, 2030
(6 years from now) | |
| US9415009 | ASTRAZENECA | Compositions, methods and systems for respiratory delivery of two or more active agents |
May, 2030
(6 years from now) | |
Drugs and Companies using BUDESONIDE; FORMOTEROL FUMARATE ingredient
Market Authorisation Date: 28 April, 2023
Treatment: Maintenance treatment of patients with chronic obstructive pulmonary disease (copd)
Dosage: AEROSOL, METERED;INHALATION
SYMBICORT AEROSPHERE family patents
22. Tagrisso patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11524951 | ASTRAZENECA | 2-(2,4,5-substituted-anilino)pyrimidine compounds |
Jul, 2032
(8 years from now) | |
| US9732058 | ASTRAZENECA | 2-(2,4,5-substituted-anilino)pyrimidine compounds |
Jul, 2032
(8 years from now) | |
| US8946235 | ASTRAZENECA | 2-(2,4,5-substituted-anilino) pyrimidine compounds |
Aug, 2032
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10183020 | ASTRAZENECA | Pharmaceutical compositions comprising AZD9291 |
Jan, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-176) | Apr 18, 2025 |
| Orphan Drug Exclusivity(ODE-337) | Dec 18, 2027 |
| Orphan Drug Exclusivity(ODE-102) | Nov 13, 2022 |
| New Indication(I-774) | Apr 18, 2021 |
| New Indication(I-853) | Dec 18, 2023 |
| Orphan Drug Exclusivity(ODE) | Nov 13, 2022 |
| New Chemical Entity Exclusivity(NCE) | Nov 13, 2020 |
Drugs and Companies using OSIMERTINIB MESYLATE ingredient
NCE-1 date: 14 November, 2019
Market Authorisation Date: 13 November, 2015
Treatment: Treatment of patients with metastatic non-small cell lung cancer (nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21l858r mutations; Adjuvant therapy after t...
Dosage: TABLET;ORAL
TAGRISSO family patents
23. Truqap patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10059714 | ASTRAZENECA | Protein kinase B inhibitors |
Oct, 2028
(4 years from now) | |
| US8101623 | ASTRAZENECA | Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor |
Mar, 2030
(5 years from now) | |
| US9487525 | ASTRAZENECA | Crystalline forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl) piperidine-4-carboxamide |
Apr, 2033
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9006430 | ASTRAZENECA | Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein |
Oct, 2025
(1 year, 6 months from now) | |
| US8809336 | ASTRAZENECA | Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein kinases inhibitors |
Oct, 2025
(1 year, 6 months from now) | |
| US10654855 | ASTRAZENECA | Protein kinase B inhibitors |
Oct, 2028
(4 years from now) | |
| US11760760 | ASTRAZENECA | Protein kinase B inhibitors |
Oct, 2028
(4 years from now) | |
| US10039766 | ASTRAZENECA | Crystalline forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d] pyrimidin-4-y1) piperidine-4-carboxamide |
Apr, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 16, 2028 |
Drugs and Companies using CAPIVASERTIB ingredient
NCE-1 date: 17 November, 2027
Market Authorisation Date: 16 November, 2023
Treatment: Treatment with fulvestrant of hr-pos. her2-neg. locally advanced or metastatic breast cancer with pik3ca/akt1/pten-alteration(s) following progression on endocrine therapy in the metastatic setting or...
Dosage: TABLET;ORAL
TRUQAP family patents
24. Zomig-zmt patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5466699 | ASTRAZENECA | Indolyl compounds for treating migraine |
Nov, 2012
(11 years ago) | |
|
US5466699 (Pediatric) | ASTRAZENECA | Indolyl compounds for treating migraine |
May, 2013
(10 years ago) | |
Drugs and Companies using ZOLMITRIPTAN ingredient
Market Authorisation Date: 13 February, 2001
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
ZOMIG-ZMT family patents